Skip to main navigation
Skip to search
Skip to main content
King's College London Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Adeel Saleem
Mr
344
Citations
Overview
Fingerprint
Network
Research output
(4)
Similar Profiles
(12)
Research output
3
Article
1
Review article
Research output per year
Research output per year
3 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Article
Search results
2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
CALM Study Group
,
Nov 2022
,
In:
The Lancet Haematology.
9
,
11
,
p. e833-e843
Research output
:
Contribution to journal
›
Article
›
peer-review
Patient
100%
Adult
100%
Acute B-Cell Lymphoblastic Leukemia
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Antileukemic Agent
28%
57
Citations (Scopus)
2021
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive
Mohseni, Y. R.
,
Saleem, A.
,
Tung, S. L.
,
Dudreuilh, C.
,
Lang, C.
,
Peng, Q.
,
Volpe, A.
, Adigbli, G., Cross, A., Hester, J.,
Farzaneh, F.
,
Scotta, C.
,
Lechler, R. I.
, Issa, F., Fruhwirth, G. O. &
Lombardi, G.
,
Oct 2021
,
In:
European Journal of Immunology.
51
,
10
,
p. 2522-2530
9 p.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
Regulatory T Cell
100%
Human T Regulatory Cell
100%
Transplant Procedure
40%
22
Citations (Scopus)
2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
UCART19 Group
,
12 Dec 2020
,
In:
The Lancet.
396
,
10266
,
p. 1885-1894
10 p.
Research output
:
Contribution to journal
›
Article
›
peer-review
Pediatrics
100%
Patient
100%
Donor
100%
Adult
100%
Acute B-Cell Lymphoblastic Leukemia
100%
232
Citations (Scopus)